These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32072462)

  • 21. Leukotriene Signaling as a Target in α-Synucleinopathies.
    Strempfl K; Unger MS; Flunkert S; Trost A; Reitsamer HA; Hutter-Paier B; Aigner L
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing α-Synuclein Oligomers.
    Umeda T; Hatanaka Y; Sakai A; Tomiyama T
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients.
    Di Salvo E; Patella V; Casciaro M; Gangemi S
    Pulm Pharmacol Ther; 2020 Feb; 60():101875. PubMed ID: 31837440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.
    Crews L; Spencer B; Desplats P; Patrick C; Paulino A; Rockenstein E; Hansen L; Adame A; Galasko D; Masliah E
    PLoS One; 2010 Feb; 5(2):e9313. PubMed ID: 20174468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Novel Potential Therapeutic Utility of Montelukast in Alleviating Autistic Behavior Induced by Early Postnatal Administration of Thimerosal in Mice.
    Abdelzaher LA; Hussein OA; Ashry IEM
    Cell Mol Neurobiol; 2021 Jan; 41(1):129-150. PubMed ID: 32303879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression.
    Kito Y; Kachi K; Yoshida M; Hori Y; Kato A; Sahashi H; Toyohara T; Kuno K; Adachi A; Urakabe K; Kataoka H
    Molecules; 2024 Jul; 29(14):. PubMed ID: 39064957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Montelukast Ameliorates Scopolamine-induced Alzheimer's Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF.
    Yerraguravagari B; Penchikala NP; Kolusu AS; Ganesh GS; Konduri P; Nemmani KVS; Samudrala PK
    CNS Neurol Disord Drug Targets; 2024; 23(8):1040-1055. PubMed ID: 37779395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
    Venugopal N; Acharya P; Zarei M; Talahalli RR
    Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA).
    Lee SY; Kim HB; Kim JH; Kim BS; Kang MJ; Jang SO; Seo HJ; Hong SJ
    Clin Exp Allergy; 2007 Oct; 37(10):1487-93. PubMed ID: 17883728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
    Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromodulatory effects of leukotriene receptor antagonists: A comprehensive review.
    Sood R; Anoopkumar-Dukie S; Rudrawar S; Hall S
    Eur J Pharmacol; 2024 Sep; 978():176755. PubMed ID: 38909933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.
    Di Gennaro A; Araújo AC; Busch A; Jin H; Wågsäter D; Vorkapic E; Caidahl K; Eriksson P; Samuelsson B; Maegdefessel L; Haeggström JZ
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1907-1912. PubMed ID: 29432192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Montelukast reduces inhaled chlorine triggered airway hyperresponsiveness and airway inflammation in the mouse.
    Hamamoto Y; Ano S; Allard B; O'Sullivan M; McGovern TK; Martin JG
    Br J Pharmacol; 2017 Oct; 174(19):3346-3358. PubMed ID: 28718891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Montelukast and Coronavirus Disease 2019: A Scoping Review.
    Sharifinejad N; Sharafian S; Salekmoghadam S; Tavakol M; Qorbani M
    Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):384-393. PubMed ID: 34418892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LTA4H rs2660845 association with montelukast response in early and late-onset asthma.
    Maroteau C; Espuela-Ortiz A; Herrera-Luis E; Srinivasan S; Carr F; Tavendale R; Wilson K; Hernandez-Pacheco N; Chalmers JD; Turner S; Mukhopadhyay S; Maitland-van der Zee AH; Burchard EG; Pino-Yanes M; Young S; Lassi G; Platt A; Palmer CNA;
    PLoS One; 2021; 16(9):e0257396. PubMed ID: 34550981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1.
    Biagioli M; Carino A; Marchianò S; Roselli R; Di Giorgio C; Bordoni M; Fiorucci C; Sepe V; Conflitti P; Limongelli V; Distrutti E; Baldoni M; Zampella A; Fiorucci S
    Biochem Pharmacol; 2020 Jul; 177():113987. PubMed ID: 32330496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors.
    Singh P; Sharma B
    Curr Neurovasc Res; 2016; 13(1):10-21. PubMed ID: 26500103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levocetirizine and montelukast in the COVID-19 treatment paradigm.
    May BC; Gallivan KH
    Int Immunopharmacol; 2022 Feb; 103():108412. PubMed ID: 34942461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
    Holma R; Salmenperä P; Riutta A; Virtanen I; Korpela R; Vapaatalo H
    Eur J Pharmacol; 2001 Oct; 429(1-3):309-18. PubMed ID: 11698051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.